UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No.        )*

 

Kintara Therapeutics, Inc.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

49720K101

(CUSIP Number)

 

August 19, 2020

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

1
 

 

 

SCHEDULE 13G

(Amendment No.      )

 

CUSIP NO. 49720K101

 

1

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

Carolyn A. Pilkiewicz

2

CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP

 

(a)

(b) X*

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

USA

 

NUMBER OF

SHARES

5

SOLE VOTING POWER

 

81,395 

BENEFICIALLY

OWNED BY

EACH

6

SHARED VOTING POWER

 

2,176,394 (1)

REPORTING

PERSON

WITH

7

SOLE DISPOSITIVE POWER

 

81,395
 

8

SHARED DISPOSITIVE POWER

 

2,176,394

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,257,789**

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

9.15%***

12

TYPE OF REPORTING PERSON

 

IN

 

For purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, all shares of the common stock, $0.001 par value per share (the “Common Stock”) of Kintara Therapeutics, Inc. (the “Company”) beneficially owned by The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001 (“FGPRT”) may be deemed to be beneficially owned by Carolyn A. Pilkiewicz and Michael B. DeGidio as Co-Trustees of FGPRT.

 

* The reporting persons expressly disclaim (i) the existence of any group and (ii) beneficial ownership with respect to any shares other than the shares owned of record by such reporting person and as set forth below.

 

** This amount consists of: (i) 2,257,789 shares of the Common Stock held by Mrs. Pilkiewicz, including 2,176,394 shares of Common Stock held by FGPRT of which Mrs. Pilkiewicz is a beneficiary and Co-Trustee, 75,223 shares of Common Stock held by Mrs. Pilkiewicz personally and 6,172 shares of Common Stock issuable upon exercise of a warrant held by Mrs. Pilkiewicz personally. Mrs. Pilkiewicz has shared voting and investment control of the securities held by FGPRT.

 

*** Based on 24,662,299 shares of the Company’s Common Stock outstanding as of November 9, 2020.

 

2
 

 

SCHEDULE 13G

(Amendment No.      )

 

CUSIP NO. 49720K101

 

1

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

Michael B. DeGidio

2

CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP

 

(a)

(b) X*

 

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

USA

NUMBER OF

SHARES

5

SOLE VOTING POWER

 

6,544

BENEFICIALLY

OWNED BY

EACH

6

SHARED VOTING POWER

 

2,176,394

REPORTING

PERSON

WITH

7

SOLE DISPOSITIVE POWER

 

6,544
 

8

SHARED DISPOSITIVE POWER

 

2,176,394

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,182,938**

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.85%***

12

TYPE OF REPORTING PERSON

 

IN

 

* The reporting person expressly disclaims (i) the existence of any group and (ii) beneficial ownership with respect to any shares other than the shares owned of record by such reporting person. Mr. DeGidio is Co-Trustee of FGPRT, but is not a beneficiary and disclaims beneficial ownership of the securities held FGPRT. Mr. DeGidio expressly acknowledges that he individually neither holds any beneficial ownership, nor any pecuniary interest, in such FGPRT securities.

 

** This amount consists of: (i) 2,182,938 shares of the Common Stock held by Mr. DeGidio, including 2,176,394 shares of Common Stock held by FGPRT of which Mr. DeGidio is a Co-Trustee, 4,601 shares of Common Stock held by Mr. DeGidio personally and 1,943 shares of Common Stock issuable upon exercise of a warrant held by Mr. DeGidio personally. Mr. DeGidio has shared voting and investment control of the securities held by FGPRT.

 

*** Based on 24,662,299 shares of the Company’s Common Stock outstanding as of November 9, 2020.

 

3
 

 

SCHEDULE 13G

(Amendment No.      )

 

CUSIP NO. 49720K101

 

1

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

2

CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP

 

(a)

(b) X*

 

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

New Jersey

 

NUMBER OF

SHARES

5

SOLE VOTING POWER

 

0

BENEFICIALLY

OWNED BY

EACH

6

SHARED VOTING POWER

 

2,176,394

REPORTING

PERSON

WITH

7

SOLE DISPOSITIVE POWER

 

0
 

8

SHARED DISPOSITIVE POWER

 

2,176,394

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,176,394

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.82%**

12

TYPE OF REPORTING PERSON

 

OO

 

* The reporting person expressly disclaims (i) the existence of any group and (ii) beneficial ownership with respect to any shares other than the shares owned of record by such reporting person. Mr. DeGidio expressly acknowledges that he individually neither holds any beneficial ownership, nor any pecuniary interest, in such securities.

 

** Based on 24,662,299 shares of the Company’s Common Stock outstanding as of November 9, 2020.

  

4
 

 

SCHEDULE 13G

(Amendment No. )

 

Item 1(a).

 

Name of Issuer:

 

 

 

 

 

Kintara Therapeutics, Inc. (the “Company”).

 

 

 

Item 1(b).

 

Address of Issuer’s Principal Executive Offices:

 

 

12707 High Bluff Dr., Suite 200, San Diego, CA 92130

 

 

 

Item 2(a) and (b).

 

Name of Person Filing and Address of Principal Business or Office or, if none, Residence:

 

 

 

 

 

Carolyn Pilkiewicz

 

 

The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

 

 

Michael B. DeGidio

 

 

3 Davenport Drive

 

 

Princeton Junction, NJ 08550

 

 

 

Item 2(c).

 

Citizenship:

 

 

 

 

 

Carolyn Pilkiewicz is a citizen of the United States.

 

 

The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001 was organized under the laws of the State of New Jersey.

 

 

Michael B. DeGidio is a citizen of the United States.

 

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

 

5
 

 

Item 2(d).

 

Title of Class of Securities:

 

 

 

 

 

Common Stock

 

 

 

Item 2(e).

 

CUSIP Number:

 

 

 

 

 

49720K101

 

 

 

Item 3.

 

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

 

 

 

 

 

(a)

[  ]

 

Broker or Dealer registered under Section 15 of the Act.

 

(b)

[  ]

 

Bank as defined in Section 3(a)(6) of the Act.

 

(c)

[  ]

 

Insurance Company as defined in Section 3(a)(19) of the Act.

 

(d)

[  ]

 

Investment company registered under Section 8 of the Investment Company Act of 1940.

 

(e)

[  ]

 

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 

(f)

[  ]

 

An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

 

(g)

[  ]

 

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 

(h)

[  ]

 

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i)

[  ]

 

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940

 

(j)

[  ]

 

Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

 

 

Item 4.

Ownership:

 

 

 

 

 

 

 

(a) Amount beneficially owned:    

 

 

 

 

 

 

 

Carolyn Pilkiewicz

-

2,248,617 shares.

 

 

 

 

 
    This amount consists of: 2,257,789 shares of the Common Stock held by Mrs. Pilkiewicz, including 2,176,394 shares of Common Stock held by FGPRT of which Mrs. Pilkiewicz is a beneficiary and Co-Trustee, 75,223 shares of Common Stock held by Mrs. Pilkiewicz personally, and 6,172 shares of Common Stock issuable upon exercise of a warrant held by Mrs. Pilkiewicz personally. Mrs. Pilkiewicz has shared voting and investment control of the securities held by FGPRT.    

 

 

 

 

 

 

 

The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

-

2,176,394 shares.

 

 

 

 

 

 

 

Michael B. DeGidio

-

2,176,394 shares
         
    This amount consists of: (i) 2,182,938 shares of the Common Stock held by Mr. DeGidio, including 2,176,394 shares of Common Stock held by FGPRT of which Mr. DeGidio is a Co-Trustee, 4,601 shares of Common Stock held by Mr. DeGidio personally and 1,943 shares of Common Stock issuable upon exercise of a warrant held by Mr. DeGidio personally. Mr. DeGidio has shared voting and investment control of the securities held by FGPRT.    

 

 

 

 

 

 

 

(b) Percent of class:

 

 

 

 

 

 

 

Carolyn Pilkiewicz

-

9.15%

 

 

The Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

-

8.82%.

 

 

Michael B. DeGidio

-

8.85%

 

 

 

 

 

 

 

(c) Number of shares as to which the person has:

 

6
 

 

 

 

 

(i) Sole power to vote or to direct the vote:

 

 

 

 

 

 

 

 

 

Carolyn Pilkiewicz

-

81,395 shares.

 

 

 

Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

-

-0- shares.

 

 

 

Michael B. DeGidio

-

6,544 shares.

 

 

 

 

 

 

 

 

 

(ii) Shared power to vote or to direct the vote:

 

 

 

 

 

 

 

 

 

Carolyn Pilkiewicz

-

2,176,394 shares.

 

 

 

Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

-

2,176,394 shares.

 

 

 

Michael B. DeGidio

-

2,176,394 shares.

 

 

 

 

 

 

 

 

 

(iii) Sole power to dispose or to direct the disposition of:

 

 

 

 

 

 

 

 

 

Carolyn Pilkiewicz

-

81,395 shares.

 

 

 

Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

-

-0- shares.

 

 

 

Michael B. DeGidio

-

6,544 shares.

 

 

 

 

 

 

 

 

 

(iv) Shared power to dispose or to direct the disposition of:

 

 

 

 

 

 

 

 

 

Carolyn Pilkiewicz

-

2,176,394 shares.

 

 

 

Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001

-

2,176,394 shares.

 

 

 

Michael B. DeGidio

-

2,176,394 shares.

 

 

 

  

Mrs. Pilkiewicz has voting and dispositive power of: 2,257,789 shares of the Common Stock held by Mrs. Pilkiewicz, including 2,176,394 shares of Common Stock held by FGPRT of which Mrs. Pilkiewicz is a beneficiary and Co-Trustee, 75,223 shares of Common Stock held by Mrs. Pilkiewicz personally, and 6,172 shares of Common Stock issuable upon exercise of a warrant held by Mrs. Pilkiewicz personally. Mrs. Pilkiewicz has shared voting and investment control of the securities held by FGPRT.

 

 

 

Item 5.

Ownership of Five Percent or Less of a Class:

 

 

 

 

 

Not Applicable.

 

 

 

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person:

 

 

 

 

 

Not Applicable

 

 

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

 

 

 

 

 

Not Applicable

 

 

 

Item 8.

Identification and Classification of Members of the Group:

 

 

 

 

 

Not Applicable

 

 

 

Item 9.

Notice of Dissolution of Group:

 

 

 

 

 

Not Applicable

 

 

 

Item 10.

Certification:

 

 

 

 

 

By signing below each of Carolyn Pilkiewicz, Frank G. Pilkiewicz Revocable Trust dtd 10-17-2001, and Michael B. DeGidio certifies that, to the best of such reporting person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

7
 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: November 16, 2020

 

 

 

 

By:

/S/ Carolyn Pilkiewicz

  

 

Carolyn Pilkiewicz, Co-Trustee

  

 

 

 

By:

/S/ Michael B. DeGidio

  

 

Michael B. DeGidio

  
     

FRANK G. PILKIEWICZ REVOCABLE TRUST DTD 10-17-2001

 

 

 

 

By:

/S/ Carolyn Pilkiewicz

 

 

Carolyn Pilkiewicz, Co-Trustee

 

 

 

 

By:

/S/ Michael B. DeGidio

 

 

Michael B. DeGidio, Co-Trustee

 

 

8
 

 

Exhibit 1

 

 

JOINT FILING AGREEMENT

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

 

Dated: November 16, 2020

 

 

 

 

By:

/S/ Carolyn Pilkiewicz

  

 

Carolyn Pilkiewicz, Co-Trustee

  

 

 

 

By:

/S/ Michael B. DeGidio

  

 

Michael B. DeGidio

  
     

FRANK G. PILKIEWICZ REVOCABLE TRUST DTD 10-17-2001

 

 

 

 

By:

/S/ Carolyn Pilkiewicz

 

 

Carolyn Pilkiewicz, Co-Trustee

 

 

 

 

By:

/S/ Michael B. DeGidio

 

 

Michael B. DeGidio, Co-Trustee

 

 

9
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Kintara Therapeutics Charts.
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Kintara Therapeutics Charts.